Staar Surgical Q1 Signals Potential Turnaround
Staar Surgical reported May 13 Q1 revenue of $93.5 million, up more than 100% and above Wall Street’s $77.4 million forecast, after earlier Alcon takeover talks were rejected by shareholders. The company cited normalization of excess China channel inventory and “strong early demand” for its EVO+ lens. Analysts raised targets (Wedbush to $40; Jefferies to $29).
How this was made
The 30-second read
Why it matters
The earnings beat reframes 2025 challenges as largely resolved, supported by operational progress (inventory normalization, manufacturing scaling) and demand catalysts (EVO+ launch in China, FDA expanded age indication in the U.S.). However, the company’s decision to defer full-year guidance until end of Q2 limits forward visibility.
Market read
Material turnaround signals for STAA: Q1 beat, China recovery evidence, and U.S. addressable-market expansion, alongside rising analyst targets.
What to watch
Middle East/India trade disruption impacted net sales by < $2M, but tariff/import execution and sustained distributor inventory discipline remain key swing factors for subsequent quarters.
Background
Staar previously faced excess China channel inventory and disruption tied to the failed Alcon takeover process; leadership changes in early 2026 positioned interim co-CEOs to steer a turnaround.
Ticker impact
Staar reported Q1 revenue more than doubled to $93.5M, citing normalization of China channel inventory and strong EVO+ early demand.
Likely supports continued upside momentum, but guidance withheld until end of Q2 keeps near-term volatility elevated.
The article provides fresh, company-specific datapoints (Q1 revenue beat, China inventory normalization, EVO+ launch demand, FDA age-indication expansion) and contemporaneous analyst target raises.
Market effects
Signals potential stabilization in ICL demand dynamics in China, which can lift sentiment across refractive/ophthalmic device names tied to China procedure volumes.
China-specific channel inventory normalization and improved refractive conditions are the core regional driver for near-term demand expectations.
Tariff-avoidance via Swiss manufacturing ramp and U.S. age-indication expansion broaden addressable markets, reinforcing global growth assumptions.
Counterpoint
Without full-year guidance until end of Q2, the turnaround may be early; China distributor restocking could reverse if demand softens again.
Key entities
- companyStaar Surgical Co.
Subject of the article; reported Q1 revenue rebound, China inventory normalization, EVO+ early demand, and FDA age-indication expansion.
- companyAlcon
Earlier takeover bidder whose process disruption affected Staar; bid was rejected by shareholders.
- investorBroadwood Partners L.P.
Holds ~31% stake and led shareholder revolt rejecting Alcon’s offer.
- analyst_firmWedbush
Upgraded STAA to Outperform and raised price target to $40, citing near-term China inflection.
- analyst_firmJefferies
Raised price target to $29 but kept Hold rating, citing cautious macro but improving demand drivers.
